AU2019256517B2 - Animal pathogen-derived polypeptides and uses thereof for genetic engineering - Google Patents

Animal pathogen-derived polypeptides and uses thereof for genetic engineering Download PDF

Info

Publication number
AU2019256517B2
AU2019256517B2 AU2019256517A AU2019256517A AU2019256517B2 AU 2019256517 B2 AU2019256517 B2 AU 2019256517B2 AU 2019256517 A AU2019256517 A AU 2019256517A AU 2019256517 A AU2019256517 A AU 2019256517A AU 2019256517 B2 AU2019256517 B2 AU 2019256517B2
Authority
AU
Australia
Prior art keywords
seq
gene
amino acid
xaa xaa
nbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019256517A
Other languages
English (en)
Other versions
AU2019256517A1 (en
Inventor
Alister P.W. FUNNELL
John A. Stamatoyannopoulos
Fyodor Urnov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altius Institute for Biomedical Sciences
Original Assignee
Altius Inst For Biomedical Sciences
Altius Institute for Biomedical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altius Inst For Biomedical Sciences, Altius Institute for Biomedical Sciences filed Critical Altius Inst For Biomedical Sciences
Publication of AU2019256517A1 publication Critical patent/AU2019256517A1/en
Application granted granted Critical
Publication of AU2019256517B2 publication Critical patent/AU2019256517B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019256517A 2018-04-18 2019-04-18 Animal pathogen-derived polypeptides and uses thereof for genetic engineering Active AU2019256517B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862659656P 2018-04-18 2018-04-18
US62/659,656 2018-04-18
US201862690905P 2018-06-27 2018-06-27
US62/690,905 2018-06-27
US201862716223P 2018-08-08 2018-08-08
US62/716,223 2018-08-08
US201862738825P 2018-09-28 2018-09-28
US62/738,825 2018-09-28
US201962819237P 2019-03-15 2019-03-15
US62/819,237 2019-03-15
PCT/US2019/028174 WO2019204643A2 (en) 2018-04-18 2019-04-18 Animal pathogen-derived polypeptides and uses thereof for genetic engineering

Publications (2)

Publication Number Publication Date
AU2019256517A1 AU2019256517A1 (en) 2020-11-12
AU2019256517B2 true AU2019256517B2 (en) 2025-05-29

Family

ID=68240638

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019256517A Active AU2019256517B2 (en) 2018-04-18 2019-04-18 Animal pathogen-derived polypeptides and uses thereof for genetic engineering

Country Status (6)

Country Link
US (2) US12312383B2 (https=)
EP (1) EP3781193A4 (https=)
JP (2) JP2021523733A (https=)
AU (1) AU2019256517B2 (https=)
CA (1) CA3097648A1 (https=)
WO (1) WO2019204643A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4010004A4 (en) * 2019-08-07 2023-09-13 Altius Institute For Biomedical Sciences Compositions and methods for modulation of gene expression
JP7507242B2 (ja) * 2020-08-25 2024-06-27 中興通訊股▲ふん▼有限公司 無線ネットワーク一時識別子に関連する方法および装置
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2025034754A2 (en) * 2023-08-08 2025-02-13 Altius Institute For Biomedical Sciences Nucleic acid binding domains and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013152220A2 (en) * 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
WO2014018601A2 (en) * 2012-07-24 2014-01-30 Cellectis New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140474D1 (de) * 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) * 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
JP5866283B2 (ja) 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ， インコーポレイテッド トリヌクレオチド反復疾患を治療するための方法および組成物
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
EP2534163B1 (en) 2010-02-09 2015-11-04 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス， インコーポレイテッド 新規のｄｎａ結合タンパク質及びその使用
US9499592B2 (en) 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
WO2012168304A1 (en) 2011-06-07 2012-12-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Protein having nuclease activity, fusion proteins and uses thereof
CA2841710C (en) 2011-07-15 2021-03-16 The General Hospital Corporation Methods of transcription activator like effector assembly
WO2013015220A1 (ja) 2011-07-22 2013-01-31 株式会社東芝 Ｘ線診断装置及び制御プログラム
AU2012312260B2 (en) 2011-09-21 2017-08-31 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
AU2012340213B2 (en) 2011-11-16 2017-12-07 Sangamo Therapeutics, Inc. Modified DNA-binding proteins and uses thereof
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
DK3141259T3 (da) 2012-03-15 2019-09-30 Cellectis Repeat-variable direster til targeting af nukleotider
DK2893022T3 (da) 2012-09-04 2020-07-27 Scripps Research Inst Kimæriske polypeptider med målrettet bindingsspecificitet
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
WO2014071219A1 (en) 2012-11-01 2014-05-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
ES2778033T3 (es) 2012-11-16 2020-08-07 Poseida Therapeutics Inc Enzimas específicas de sitio y métodos de uso
US9708589B2 (en) 2012-12-18 2017-07-18 Monsanto Technology Llc Compositions and methods for custom site-specific DNA recombinases
US20150376585A1 (en) 2013-02-01 2015-12-31 Cellectis Tevi chimeric endonuclease and their preferential cleavage sites
KR102251168B1 (ko) 2013-10-25 2021-05-13 셀렉티스 고 반복 모티프를 포함하는 dna 서열에 대한 효율적이고 특이적인 표적화를 위한 희소-절단 엔도뉴클레아제의 설계
US9850497B2 (en) 2013-11-04 2017-12-26 Regents Of The University Of Minnesota Gene targeting methods and tools
WO2015164748A1 (en) 2014-04-24 2015-10-29 Sangamo Biosciences, Inc. Engineered transcription activator like effector (tale) proteins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
US11353400B2 (en) 2016-07-19 2022-06-07 Altius Institute For Biomedical Sciences Methods for fluorescence imaging microscopy and Nano-FISH
CN110312799A (zh) 2016-08-17 2019-10-08 博德研究所 新型crispr酶和系统
SG10201913948PA (en) 2016-08-24 2020-03-30 Sangamo Therapeutics Inc Engineered target specific nucleases
AU2018221730B2 (en) 2017-02-15 2024-06-20 Novo Nordisk A/S Donor repair templates multiplex genome editing
US12264181B2 (en) 2018-06-27 2025-04-01 Altius Institute For Biomedical Sciences Nucleic acid binding domains and methods of use thereof
WO2020006131A2 (en) 2018-06-27 2020-01-02 Altius Institute For Biomedical Sciences Nucleases for genome editing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013152220A2 (en) * 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
WO2014018601A2 (en) * 2012-07-24 2014-01-30 Cellectis New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BURSTEIN D. et al., "Genomic analysis of 38 Legionella species identifies large and diverse effector repertoires", NATURE GENETICS. 2016, vol. 48, pages 167 - 175 *
R. JANKELE ET AL: "TAL effectors: tools for DNA Targeting", BRIEFINGS IN FUNCTIONAL GENOMICS, vol. 13, no. 5, 6 June 2014 (2014-06-06), Oxford, UK, pages 409 - 419, XP055273314, ISSN: 2041-2649, DOI: 10.1093/bfgp/elu013 *

Also Published As

Publication number Publication date
US12312383B2 (en) 2025-05-27
EP3781193A4 (en) 2022-01-26
WO2019204643A3 (en) 2019-11-28
JP2021523733A (ja) 2021-09-09
US20250361275A1 (en) 2025-11-27
CA3097648A1 (en) 2019-10-24
AU2019256517A1 (en) 2020-11-12
US20210115093A1 (en) 2021-04-22
EP3781193A2 (en) 2021-02-24
WO2019204643A2 (en) 2019-10-24
JP2025037883A (ja) 2025-03-18

Similar Documents

Publication Publication Date Title
AU2019256517B2 (en) Animal pathogen-derived polypeptides and uses thereof for genetic engineering
AU2021200127B2 (en) Delivery of negatively charged proteins using cationic lipids
ES2808687T3 (es) Métodos y composiciones para escisión dirigida y recombinación
US20250289853A1 (en) Nucleic acid binding domains and methods of use thereof
ES2543409T3 (es) Métodos y composiciones para la escisión y recombinación dirigidas
US7972854B2 (en) Methods and compositions for targeted cleavage and recombination
EP4434997A2 (en) Delivery of negatively charged proteins using cationic lipids
US12275935B2 (en) Gapped and tunable repeat units for use in genome editing and gene regulation compositions
WO2021026336A2 (en) Compositions and methods for modulation of gene expression
WO2024240226A1 (en) Methods of forming circularized rna
US12467077B2 (en) Compositions and methods for DNA modification detection
US20230399660A1 (en) Cell Permeable Proteins for Genome Engineering
US20220290188A1 (en) Compositions and Methods for Modulation of Gene Expression
US20220220171A1 (en) Cell permeable proteins for genome engineering
AU2007201649A1 (en) Methods and Compositions for Targeted Cleavage and Recombination
HK1215046B (en) Methods and compositions for targeted cleavage and recombination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)